Directory
>
Kathryn Woodburn
Kathryn Woodburn
Sr Vice President, Preclinical Development | Life Edit Therapeutics
San Francisco, California, United States
Kathryn Woodburn
Summary
Kathryn Woodburn is an accomplished leader in preclinical development with a robust background in pharmacology and drug development. With extensive experience in gene therapy, oncology, and cardiology, she has successfully guided numerous projects from research through to FDA approval. Kathryn has been instrumental in the development of Hematide, showcasing her expertise in navigating complex regulatory environments. As a regular presenter at scientific conferences and a prolific author, she has contributed significantly to the field through both publications and patents. Currently serving as Sr Vice President at Life Edit, she is also a co-chair of the Biosafe Gene Therapy Committee, reflecting her commitment to advancing gene editing technologies. Her educational background includes a PhD in Chemistry from La Trobe University, further solidifying her technical foundation. Kathryn's unique blend of scientific acumen and leadership experience positions her as a pivotal figure in the pharmaceutical industry.
Kathryn Woodburn
Work Experience
Sr Vice President, Preclinical Development at
Life Edit Therapeutics
August 2021 - Present
Independent Consultant at
Pharmacotox Consulting
February 2013 - August 2021
Executive Director, Preclinical Development at
Adverum Biotechnologies
February 2014 - January 2017
Executive Director, Preclinical Development at
AFFYMAX LIMITED
July 2007 - November 2012
Sr Director, Preclinical Development at
AFFYMAX LIMITED
December 2002 - July 2007
Director of Preclinical Research at
AP Pharma
October 2001 - November 2002
Director of Preclinical Research at
Pharmacyclics, an AbbVie Company
September 1994 - September 2001
Kathryn Woodburn
Education
Wayne State University School of Medicine, Post Doctoral Fellow
January 1992 - January 1994
University of Toledo, Post Doctoral Research Fellow
January 1992 - January 1992
La Trobe University, Phd
January 1988 - January 1992
La Trobe University, Bsc (Hons)
January 1987 - January 1987
Frequently Asked Questions about Kathryn Woodburn
What is Kathryn Woodburn email address?
Kathryn Woodburn's primary email address is *********@lifeeditinc.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Kathryn Woodburn work for?
Kathryn Woodburn is a Sr Vice President, Preclinical Development at Life Edit Therapeutics, a company specializing in Commercial physical research.
Where Kathryn Woodburn graduated from?
Kathryn Woodburn holds a degree in Pharmacology from Wayne State University School of Medicine.
How can I directly contact Kathryn Woodburn?
To contact Kathryn Woodburn directly, you can use the email address *********@lifeeditinc.com. Complete contact information is available upon registration with Muraena.
Who is Kathryn Woodburn?
Kathryn Woodburn is an accomplished leader in preclinical development with a robust background in pharmacology and drug development. With extensive experience in gene therapy, oncology, and cardiology, she has successfully guided numerous projects from research through to FDA approval. Kathryn has been instrumental in the development of Hematide, showcasing her expertise in navigating complex regulatory environments. As a regular presenter at scientific conferences and a prolific author, she has contributed significantly to the field through both publications and patents. Currently serving as Sr Vice President at Life Edit, she is also a co-chair of the Biosafe Gene Therapy Committee, reflecting her commitment to advancing gene editing technologies. Her educational background includes a PhD in Chemistry from La Trobe University, further solidifying her technical foundation. Kathryn's unique blend of scientific acumen and leadership experience positions her as a pivotal figure in the pharmaceutical industry.
Kathryn`s contact details
*********@lifeeditinc.com
Colleagues
Vice President of Membership
Vice President Of CRISPR Technology Development
Chief Operating Officer
Head of Alliance Management, Vice President
Vice President, Computational Biology & Bioinformatics